NCT Number: NCT06637189
The PPOS protocol (Progestin-primed Ovarian Stimulation) involves avoiding ovulation during ovarian stimulation with progesterone. It is a reliable and safe protocol that has been widely used in recent years for in vitro fertilization, as it reduces the number of injections needed during controlled ovarian stimulation and is more cost-effective for patients.
The aim of this study is to compare two methods of ovarian stimulation for in vitro fertilization: the PPOS protocol (Group A) and the conventional protocol with injected antagonists (Group B). The goal is to determine whether both methods are equally effective in obtaining euploid embryos in the context of double ovarian stimulation.
Trial opening soon.
Get Notified18 year–43 year
Female
Interventional
Phase 4
Hypothesis:
Hypothesis: The number of euploid embryos obtained in a DUOSTIM cycle with PPOS is not inferior to that obtained with the use of antagonists.
General and Specific Objectives
Main Objective: To study if there is a difference in the number of euploid embryos obtained in two groups of patients undergoing embryo accumulation for PGT-A through double ovarian stimulation, comparing two methods of pituitary suppression: Progesterone use from the start of stimulation and the use of GnRH antagonists.
Secondary Objectives:
Evaluate if there are differences between both groups regarding the number of MII oocytes.
Evaluate if there are differences between both groups regarding the number of cumulus-oocyte complexes (COC).
Study the differences between both groups regarding the total consumption of gonadotropins.
Evaluate if there are differences between both groups regarding the number of stimulation days.
Evaluate if there are differences in fertilization rate after microinjection. Evaluate if there are differences between both groups regarding the cancellation rate.
Evaluate if there are differences between both groups regarding the number of total embryos.
Evaluate if there are differences between both groups regarding the number of embryos subjected to trophectoderm biopsy.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitively binding to GnRH receptors in the pituitary gland. Consequently, there is a reversible, intense, and rapid suppression of endogenous gonadotropin release. Ganirelix is indicated for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive techniques (ART).
Medroxyprogesterone acetate is a synthetic progestin (structurally related to progesterone) with antiestrogenic, antiandrogenic, and antigonadotropic action. It inhibits pituitary gonadotropins (FSH and LH) with consequent inhibition of follicular maturation and ovulation . Medroxyprogesterone acetate is active orally and parenterally, 15 times more potent than progesterone. In addition to inhibiting ovulation, progestins also act on the endometrium preventing implantation and increasing the viscosity of cervical mucus, which hinders sperm progression in the uterus. It also transforms a proliferative endometrium into a secretory endometrium, provided that the woman has adequate endogenous estrogen levels.
Time frame: From date of randomization until the end of the treatment. Assessed up to 12 weeks.
Total number of euploid embryos after the two egg retrievals
Time frame: From date of randomization until the end of the treatment. Assessed up to 12 weeks.
Total number of oocytes retrieved after the two egg retrievals
Time frame: From date of randomization until the end of the treatment. Assessed up to 12 weeks.
Total number of metaphase II oocytes retrieved after the two egg retrievals
Time frame: From date of randomization until the end of the treatment. Assessed up to 12 weeks.
Total number of fertilized oocytes after the two egg retrievals
Time frame: From date of randomization until the end of the treatment. Assessed up to 12 weeks.
Total number of blastocyst stage embryos after the two egg retrievals
Contact information is provided by the study sponsor or research team.
Claudia Blancafort González-Casabón, MD
CONTACT
Joaquín Llácer, phD
CONTACT
Ginefiv
Other
Acronym: PPDUO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06879002
IVF Outcome, Stimulation in the Ovary
Abu Dhabi, United Arab Emirates
View Trial DetailsNCT01385332
Stimulation in the Ovary
Barcelona, Spain
View Trial DetailsNCT04935658
Agnosia, Behavior
Clermont-Ferrand, France
View Trial DetailsNCT02999958
Antioxidants, Blastocyst
Fukuoka, Japan
View Trial Details